This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
El-Jawahri A, Kim HT, Steensma DP, Cronin AM, Stone RM et al. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplant 2016, (e-pub ahead of print 21 March 2016; doi:10.1038/bmt.2016.40).
Scott BL, Pasquini MC, Logan B, Wu J, Devine S, Porter D et al Results of a phase-III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901. Available at: https://ash.confex.com/ash/2015/webprogram/Paper87386.html. (accessed on 23 March 2016).
Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013; 31: 2662–2670.
Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579–585.
Cary CK, Punnen S, Odisho AY, Litwin MS, Saigal CS, Cooperberg MR et al. Nationally-representative trends and geographic variation in treatment of localized prostate cancer: the urologic diseases in America project. Prostate Cancer Prostatic Dis 2015; 18: 149–154.
Christakis NA, Lamont EB . Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 2000; 320: 469–472.
Acknowledgements
Professors Teresa Hahn (Roswell Park Cancer Centre), Eli Estey (University of Washington), Giovanni Barosi (University of Pavia), Heidi Klepin (Wake Forest University), Cory Cutler and John Koreth (Harvard University), and Hillard Lazarus (Case Western Reserve University) kindly reviewed the typescript. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. We failed several sensitivity-training courses while formulating this typescript. Remedial work in progress.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Gale, R., Pusic, I. Transplants for MDS and quality-of-life. But whose quality-of-life?. Bone Marrow Transplant 51, 1066–1068 (2016). https://doi.org/10.1038/bmt.2016.147
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.147
This article is cited by
-
Myelodysplastic syndromes
Nature Reviews Disease Primers (2022)